- Amendis

An accurate
Diagnostic Test Read More

Better Healthcare System Read More

Avoiding Side Effects in Patients Read More

Preventing Unnecessary Surgery Read More

Providing a solution to a critical unmet need in the personalized treatment of oral cavity cancer.

Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide

Minimizing the number of patients undergoing surgery

HDNX is a diagnostic test based on genomic analysis, algorithmics and artificial intelligence (AI). It is performed on tissue obtained from the biopsy of oral cavity cancer patients.

NEWS

News and Updates

January 25, 2023

Amendis appoints Ron Mayron to the Position of Chairman

Ron Mayron has a rich experience in the pharmaceutical and medical equipment industry, having served for over 20 years in several key positions and senior management positions in the field of pharmaceuticals in the local and global market, his former

February 14, 2022

Amendis successfully completed its first clinical study on oral cavity cancer patients to predict metastasis to the neck.

As part of the clinical study, which was conducted at the Hadassah University Hospital-Ein Kerem under Helsinki approval, cancerous tissues from the tongue of head and neck cancer patients were examined. Amendis’s proprietary AI based technology was used to predict

May 26, 2020

Amendis will start a limited validation study of its predictive diagnostic test based on actual cases

Amendis, whose primary objective is to minimize unnecessary surgery on neck cancer patients, has announced that it is initiating a limited validation study of its predictive diagnostic test based on actual cases. At present, following a diagnosis of throat cancer,

All News